Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature

Background: Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer. Post-marketing use of capecitabine at the FDA-approved dose (2500mg/m2/day) leads to unacceptable toxicity in many patients. Dose reductions anecdotally improve tolerability without compromising...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2005-08, Vol.16 (8), p.1289-1296
Hauptverfasser:	Hennessy, B.T., Gauthier, A.M., Michaud, L.B., Hortobagyi, G., Valero, V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antineoplastic agents Biological and medical sciences breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - secondary Capecitabine Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Colorectal Neoplasms - drug therapy Colorectal Neoplasms - secondary Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Dose-Response Relationship, Drug Erythema - chemically induced Erythema - drug therapy Female Fluorouracil - analogs & derivatives Humans Male Maximum Tolerated Dose Medical sciences Middle Aged Pharmacology. Drug treatments Retrospective Studies Skin Diseases - chemically induced Skin Diseases - drug therapy toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!